[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"nociceptive-pain\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:nociceptive-pain":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,42,64,96,129,158,185,213,243],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100550146","pain-phenotyping-in-patients-with-neuropathic-pain-after-spinal-cord-injury-100550146",false,"NCT06443281","Pain Phenotyping in Patients With Neuropathic Pain After Spinal Cord Injury","Inclusion Criteria:\n\n* Spinal injury cohort - general inclusion criteria:\n* Aged between 18-80 years\n* Traumatic and non-traumatic etiology\n* Para- and tetraplegic SCI\n* Complete and incomplete SCI\n* SCI with and without neuropathic pain\n* Additional inclusion criteria for longitudinal study:\n* SCI since less than one month\n* Additional inclusion criteria for cross-sectional study:\n* SCI since more than one year\n* Control cohorts with peripheral neuropathy:\n* General inclusion criteria:\n* Aged between 18-80 years\n* Neurological disorder affecting the peripheral nervous system (i.e., peripheral neuropathy)\n* Peripheral neuropathy with or without neuropathic pain\n* Additional inclusion criteria for longitudinal study:\n* Peripheral neuropathy since less than one month\n* Additional inclusion criteria for cross-sectional study:\n* Peripheral neuropathy since more than one year\n* Control cohorts without neuropathy \u002F healthy volunteers\n* General inclusion criteria:\n* Aged between 18-80 years\n* No medical condition affecting the peripheral and\u002For central nervous system (e.g., pain, systemic disease, psychological disorder)\n\nExclusion Criteria:\n\n* Inability to follow study instructions\n* Pregnancy\n* Medically manifested psychological disorder\n* Medical condition affecting the peripheral and\u002For central nervous system other than the desired experimental condition (e.g., additional peripheral neuropathy in the SCI cohort)",true,"ALL","18 Years","80 Years",{"count":20,"type":21},300,"ESTIMATED","OBSERVATIONAL","The development of neuropathic pain is one of the most debilitating sequels after a spinal cord injury (SCI). The overall aim of this study is to investigate potential underlying pathophysiological mechanisms of neuropathic pain after SCI. The functionality of the nociceptive pathway in humans as well as its plastic changes following SCI will be inferred with sophisticated sensory and pain phenotyping using quantitative sensory testing (i.e., psychophysical measures), objective neurophysiological measures of pain processing and the recording of pain-related autonomic responses (i.e., galvanic skin response, cardiovascular measures and pupil dilation). In addition, the interplay between the somatosensory and autonomic nervous system and its association with the development and maintenance of neuropathic pain after SCI will be investigated.",[25,26,27,28],"Spinal Cord Injuries","Pain, Neuropathic","Nociceptive Pain","Neuropathy","RECRUITING","2026-05-12",{"date":32,"type":33},"2026-05-15","ACTUAL",{"date":35,"type":33},"2024-04-17",{"date":37,"type":21},"2030-04-30",{"name":39,"class":40},"University of Zurich","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":41},"100529275","fdg-petmr-imaging-of-peripheral-pain-generators-100529275","NCT06171659","FDG PET\u002FMR Imaging of Peripheral Pain Generators","FDG PET\u002FMR Imaging of Peripheral Pain Generators in Persistent Post-Surgical Pain (PPSP)","Inclusion Criteria: Persistent Post-Surgical Pain Patients\n\n* 18-85 years old\n* Presents with persistent pain with pain score of ≥4 on Numerical Rating Scale \\[0:10\\] for at least 6 months following joint arthroplasty or arthroscopy.\n* Able and willing to provide informed consent\n* Willing and able to undergo PET\u002FMRI (arthroplasty and arthroscopy participants) and PET\u002FCT (arthroplasty participants only)\n\nInclusion Criteria: Asymptomatic controls\n\n* 18-85 years old\n* Asymptomatic (pain score of ≤2 on the NRS) for at least 6 months following joint arthroplasty or arthroscopy.\n* Able and willing to provide informed consent\n* Willing and able to undergo PET\u002FMRI\n\nExclusion Criteria:\n\n* Inability to understand and communicate with the investigators to complete the study-related questionnaires.\n* Any co-morbidity which results in severe systemic disease limiting function as defined by the American Society of Anesthesiology (ASA) physical status classification \\> 3, such as the presence of current or past (6 months) pulmonary, hepatic, renal disease, arthritis, hematopoietic, and neurological diseases not related to chronic pain.\n* Pregnant or breastfeeding. (Individuals with childbearing potential will be asked to verbally confirm they are not pregnant. If they cannot confirm, they will have a urine pregnancy test either at the imaging study visit or within 7 days prior to the imaging study visit.)\n* Subject with contraindication(s) to or inability to undergo PET\u002FMRI\n* Current diagnosis of malignancy of any kind. Participants in remission for at least two years and not undergoing any treatment may be considered per investigator discretion\n* Current enrollment in a scientific interventional or treatment study.\n* Subject unable or unwilling to provide informed consent","85 Years",{"count":51,"type":21},128,"The purpose of this research is to determine if a PET\u002FMRI scan using FDG can accurately identify the source of chronic pain. Identifying the source of pain may help doctors treat chronic pain more effectively. Approximately 128 participants will be enrolled and can expect to be on study for up to 12 months.",[54,27],"Pain","2025-09-24",{"date":57,"type":33},"2025-09-25",{"date":59,"type":33},"2024-11-19",{"date":61,"type":21},"2027-06",{"name":63,"class":40},"University of Wisconsin, Madison",{"id":65,"slug":66,"hasResults":11,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":70,"eligibilityCriteria":71,"healthyVolunteers":11,"sex":16,"minAge":72,"maxAge":73,"enrollmentInfo":74,"targetDuration":76,"studyType":22,"phases":4,"briefSummary":77,"conditions":78,"keywords":82,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":41},"100599472","comparison-of-the-surgical-pleth-index-and-the-nociception-level-index-in-the-pediatric-population-100599472","NCT07084935","Comparison of the Surgical Pleth Index and the Nociception Level Index in the Pediatric Population","Comparison of the Surgical Pleth Index and the Nociception Level Index in the Pediatric Population: An Observational Study","NOLvsSPI","Inclusion Criteria:\n\n* Male or female\n* ASA I, ASA II and ASA III\n* Aged 1 to 12 years old\n* Scheduled to undergo elective surgery with general anaesthesia\n\nExclusion Criteria:\n\n* Patients with chronic pain\n* Patients with chronic analgesia usage.\n* Known allergy to the adhesives used in the sensors.\n* No free available limb to attach the probes to.","1 Year","12 Years",{"count":75,"type":21},40,"1 Day","This observational study aims to compare two nociception monitoring methods. The Nociception Level (NOL) index and the Surgical Pleth Index (SPI) in the pediatric population during general anesthesia. While both monitors are designed to assess nociceptive responses through autonomic nervous system activity, they differ in methodology and parameters measured. The NOL index integrates multiple physiological signals using a self-learning algorithm, while SPI focuses on heart rate variability and plethysmographic amplitude. Although both have been studied individually in children, a direct comparison has not yet been conducted. This study will evaluate and compare each monitor's ability to detect and quantify nociceptive stimuli (surgical and tetanic) in children.\n\nThe investigators hypothesize that the NOL monitor and SPI monitor will both be able to quantify surgical stimuli and tetanic stimuli with monitors response to surgical stimuli \\> monitors response to tetanic stimuli. However, the investigators also hypothesize that the NOL index will do this superiorly, as it utilizes a self-learning algorithm and more parameters are incorporated in its algorithm",[27,79,80,81],"Anesthesia","Pediatric Anesthesia","Nociception Monitoring",[83,84,85,86],"Nociception monitoring","Pediatric population","NOL index","Surgical pleth index","2025-07-24",{"date":89,"type":33},"2025-07-25",{"date":91,"type":33},"2025-07-04",{"date":93,"type":21},"2026-07-31",{"name":95,"class":40},"Radboud University Medical Center",{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":102,"eligibilityCriteria":103,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":104,"targetDuration":4,"studyType":106,"phases":107,"briefSummary":109,"conditions":110,"keywords":115,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":41},"100585667","guiding-opioid-administration-by-nociception-level-index-nol-in-patients-with-regional-anesthesia-100585667","NCT06905340","Guiding Opioid Administration by Nociception Level Index (NOL) in Patients With Regional Anesthesia","Nociception Level Index-Guided Intraoperative Opioids in Patients With a Combination of General and Regional Anesthesia","NORA","Inclusion Criteria:\n\n\\- Patients undergoing elective trauma or orthopedic surgery with a combination of general and regional anesthesia\n\nExclusion Criteria:\n\n* Preexisting therapy with cardiac glycosides or pacemakers\n* Cardiac arrhythmia (atrial fibrillation, atrioventricular block \\> I°)\n* Chronic opioid misuse\n* Intraoperative treatment with ketamine, beta-adrenergic agonists, or clonidine\n* Serious peripheral or cardiac autonomic neuropathy\n* Inability to specify the postoperative pain level\n* Postoperative treatment in an ICU",{"count":105,"type":21},240,"INTERVENTIONAL",[108],"NA","General anesthesia consists of a combination of hypnotic drugs to achieve unconsciousness and opioid analgesics to ensure antinociception. An alternative approach to the intraoperative administration of high-potency opioids to achieve antinociception during surgery is combining general anesthesia with regional anesthesia. Modern general anesthesia aims to avoid an overdose of opioid analgesics and reduce side effects of opioid administration. Quality and safety of general anesthesia are of major clinical importance and can be improved by adjusting the opioid analgesics to the optimal individual dose needed.\n\nIn current clinical practice, opioid dosage is usually determined by clinical judgment. However, different monitoring devices estimating the effect of nociception during unconsciousness have become commercially available. One of the most recent commercially available nociception indices is the Nociception Level Index (NOL). Until today, there is conflicting evidence on whether guiding sufentanil administration by NOL monitoring, which is the intended use of the nociception index, affects postoperative pain level in the postanesthesia care unit (PACU), the amount of postoperatively administered opioids, and the quality of postoperative recovery in patients with a combination of general and regional anesthesia. This study aims to investigate the clinical performance of intraoperative NOL monitoring and determine whether guiding sufentanil administration by NOL monitoring - compared to routine care - reduces either postoperative pain level in the PACU, postoperative opioid consumption in the PACU or postoperative opioid consumption in the first 24 hours after the operation in patients having trauma and orthopedic surgery with combined general and regional anesthesia.",[27,111,112,113,114],"Pain, Postoperative","Analgesia, Postoperative","Anesthesia Recovery Period","Opioid Use",[116,117,118,119],"General anesthesia","Regional anesthesia","Analgesia Monitoring","Opioids","2025-06-04",{"date":122,"type":33},"2025-06-08",{"date":124,"type":33},"2025-05-12",{"date":126,"type":21},"2026-01",{"name":128,"class":40},"Universitätsklinikum Hamburg-Eppendorf",{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":4,"eligibilityCriteria":135,"healthyVolunteers":11,"sex":16,"minAge":136,"maxAge":4,"enrollmentInfo":137,"targetDuration":4,"studyType":106,"phases":139,"briefSummary":140,"conditions":141,"keywords":143,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":157},"100574774","ultra-low-frequency-neuromodulation-for-nociceptive-chronic-low-back-pain-100574774","NCT06763653","Ultra Low Frequency Neuromodulation for Nociceptive Chronic Low Back Pain","A Prospective, Multi-Center, Randomized, Controlled Trial to Compare the Safety and Efficacy of Ultra Low Frequency Spinal Cord Stimulation Plus Conservative Medical Management (CMM) to CMM Alone in the Treatment of Chronic Axial Low Back Pain With Prominent Nociceptive Etiology - The FULFILL Study","Inclusion Criteria:\n\n1. Chronic, intractable nociceptive axial low back pain with or without leg pain (VAS ≥6 cm for back pain over 7 days) for a minimum of 3 months.\n2. Symptoms have failed to respond adequately to conservative therapies, including: physical therapy\u002Fexercise, medications, and interventional therapies.\n3. Back pain greater than leg pain.\n4. ODI score ≥30 and ≤80.\n5. On stable pain medications or on no pain medications.\n6. Considered medically stable and a suitable surgical candidate.\n7. Able to operate the device.\n8. Willing to sign the Human Research Ethics Committee (HREC)\u002FInstitutional Review Board (IRB) approved informed consent form.\n9. Willing and deemed capable of complying with the requirements of the study protocol, including attending all scheduled visits.\n10. Twenty-two (22) years of age or older.\n11. Able to complete questionnaires independently.\n\nExclusion Criteria:\n\n1. Have a systemic condition or disease not stabilized or judged by the investigator to be incompatible with participation in the study.\n2. Suffer from severe cognitive impairment that would impair ability to complete subject questionnaires or operation of the device.\n3. Diagnosed with an active disruptive psychological or psychiatric disorder or other known condition significant enough to impact perception of pain, compliance, intervention and\u002For ability to evaluate treatment outcome as assessed by a clinical psychologist or psychiatrist.\n4. Presence of spinal stenosis, structural spinal abnormality, or spinal instrumentation observed on MRI or CT that would make lead placement unsafe or untowardly difficult.\n5. Previous experience with neuromodulation devices for pain.\n6. Opioid usage with average total daily morphine equivalent dose (MED) of \\>100 mg.\n7. Have an untreated addiction to alcohol or other drugs within 6 months of screening visit.\n8. Have a cardiac demand pacemaker, implanted defibrillator, or another implanted electronic device.\n9. Have a known hypersensitivity to any of the procedural agents or materials in the study device that is inserted into the subject.\n10. Have a known need for an MRI or surgery through the end of the study.\n11. Candidates of child-bearing potential cannot be pregnant nor plan to become pregnant during the study.\n12. Diagnosed with untreated malicious or malignant neoplasms or have a life expectancy of less than 1 year.\n13. Be participating in another interventional clinical trial.","22 Years",{"count":138,"type":21},303,[108],"The goal of this clinical trial is to learn if Ultra Low Frequency (ULF) neuromodulation works to treat nociceptive chronic low back pain in adults. It will also evaluate the safety of ULF therapy. The main questions it aims to answer are:\n\n* Does ULF neuromodulation reduce chronic low back pain?\n* What, if any, unexpected medical problems do participants experience when treated with ULF neuromodulation?\n\nResearchers will compare ULF therapy to conventional treatments for chronic low back pain. Participants will:\n\n* Be randomly assigned to either the study device or to conventional medical treatments\n* Undergo standard surgical procedures to place the study device if assigned to the device arm\n* Attend regular clinic visits over 24 months for checkups and data collection",[27,142],"Axial Back Pain",[144,145,146],"Neuromodulation","Spinal cord stimulation","Chronic low back pain","2025-01-21",{"date":149,"type":33},"2025-01-24",{"date":151,"type":33},"2025-01-17",{"date":153,"type":21},"2029-04",{"name":155,"class":156},"Presidio Medical, Inc","INDUSTRY",3,{"id":159,"slug":160,"hasResults":11,"nctId":161,"briefTitle":162,"officialTitle":163,"acronym":164,"eligibilityCriteria":165,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":166,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":168,"conditions":169,"keywords":171,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":176,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":184},"100519518","unveiling-physiological-and-psychosocial-pain-components-with-an-artificial-intelligence-based-telemonitoring-tool-100519518","NCT06044584","Unveiling Physiological and Psychosocial Pain Components with an Artificial Intelligence Based Telemonitoring Tool","Unveiling Physiological and Psychosocial Pain Components with an Artificial Intelligence Based Telemonitoring Tool (pAIn-sense)","pAIn-sense","Inclusion Criteria:\n\n* Ongoing nociceptive pain after an injury or Neuropathic pain (acute or chronic)\n* Familiar with using electronic devices\n\nExclusion Criteria:\n\n* Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc.\n* Unable or not willing to give informed consent",{"count":167,"type":21},150,"The pAIn-sense study aims to revolutionize the monitoring and treatment of chronic pain, a major health concern that significantly impacts psychological well-being and quality of life. Traditional approaches to pain management face challenges like unspecific drug use and high healthcare costs, and they often leave patients dissatisfied. PAIn-sense aims at comprehensively understanding pain from both physical and emotional perspectives. To accomplish this, the study will employ advanced Artificial Intelligence (AI) techniques and wearable sensing technology. The study aims to monitor patients continuously, during both day and night activities, to gather a multidimensional set of data on their physiological, psychosocial, and pain conditions.",[27,170],"Neuropathic Pain",[54,172,173,174,175],"Telemonitoring","Artificial Intelligence","Physiological signals","Psychosocial",{"date":177,"type":33},"2025-01-20",{"date":179,"type":33},"2023-09-29",{"date":181,"type":21},"2028-12-31",{"name":183,"class":40},"ETH Zurich",4,{"id":186,"slug":187,"hasResults":11,"nctId":188,"briefTitle":189,"officialTitle":190,"acronym":4,"eligibilityCriteria":191,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":192,"targetDuration":4,"studyType":106,"phases":194,"briefSummary":196,"conditions":197,"keywords":200,"overallStatus":203,"whyStopped":4,"lastUpdateSubmitDate":204,"lastUpdatePostDateStruct":205,"startDateStruct":207,"completionDateStruct":209,"leadSponsor":211,"locationsCount":4},"100562129","phase-1-petmri-for-chronic-pain-from-spinal-or-peripheral-nerve-origin-100562129","NCT06599151","PETMRI for Chronic Pain from Spinal or Peripheral Nerve Origin","Use of (18F)FTC-146 PET_MRI for Characterizing Chronic Pain Phenotypes in Chronic Pain Patients with Spinal or Peripheral Nerve Origin","Inclusion Criteria:\n\n* Healthy Volunteers\n\n  1\\. At least 18 years old.\n* Pain Subjects\n\n  1. At least 18 years old.\n  2. Chronic Pain is of Spinal or Peripheral Nerve Origin\n  3. Subject's Chronic pain lasting greater than 2 months.\n  4. Pain level of at least 4\u002F10 on a 0-10 Comparative Pain Scale.\n\nExclusion Criteria:\n\n* Healthy Volunteers\n\n  1. Any chronic Pain\n  2. Use of pain medication.\n  3. MRI incompatibility.\n  4. Kidney problems.\n  5. Pregnant or nursing.\n  6. Non-English speaker.\n  7. Presence of vasculopathy or Raynaud's.\n  8. Inability to tolerate cessation of anticoagulant medication during the study.\n* Pain Subjects\n\n  1. MRI incompatibility.\n  2. Kidney problems.\n  3. Pregnant or nursing.\n  4. Non-English speaker.",{"count":193,"type":21},200,[195],"PHASE1","The purpose of this study is to compare the uptake of \\[18F\\]FTC-146 in healthy volunteers to that of individuals suffering from chronic pain with Spinal or Peripheral Nerve Origin.\n\nPrimary Objectives:\n\nA) To quantify the bio-distribution of \\[18F\\] FTC-146 uptake in subjects with Spinal or Peripheral Nerve Origin pain and compare it with healthy controls.\n\nB) To determine whether painful schwannomas can be differentiated from non-painful schwannomas based on imaging.\n\nSecondary Objectives:\n\nA) To assess the reproducibility of \\[18F\\]FTC-146 PET imaging within the same healthy volunteer subjects using Test-Retest analysis.\n\nB) To investigate whether post-treatment \\[18F\\]FTC-146 uptake differs from pre-treatment uptake and correlate the imaging with subject reported pain level after treatment",[198,170,27,199],"Nerve Pain","MIxed Pain (Nociceptive and Neuropathic)",[201,202,198],"PET\u002FMRI","Chronic Pain","NOT_YET_RECRUITING","2024-09-12",{"date":206,"type":33},"2024-09-19",{"date":208,"type":21},"2024-10-01",{"date":210,"type":21},"2030-10-01",{"name":212,"class":40},"Stanford University",{"id":214,"slug":215,"hasResults":11,"nctId":216,"briefTitle":217,"officialTitle":218,"acronym":219,"eligibilityCriteria":220,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":221,"enrollmentInfo":222,"targetDuration":4,"studyType":106,"phases":224,"briefSummary":226,"conditions":227,"keywords":229,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":234,"lastUpdatePostDateStruct":235,"startDateStruct":237,"completionDateStruct":239,"leadSponsor":241,"locationsCount":41},"100538478","phase-4-impact-of-administration-of-esmolol-on-nociception-level-guided-control-of-nociception-100538478","NCT06291363","Impact of Administration of Esmolol on Nociception Level-guided Control of Nociception.","Impact of Continuous Intraoperative Administration of Esmolol on Nociception Level-guided Control of Nociception. The EsmoNOL Randomized Controlled Trial","ESMONOL","Inclusion Criteria:\n\n* Fully consented, American Society of Anesthesiologists Classification Score 1-3 patients from 18yo to 65yo\n* Undergoing laparoscopic surgery associated with sub umbilical mini-laparotomy. Eligible surgeries will be hysterectomy (excluding vaginal approach) and left hemicolectomy, of duration time expected under 180 minutes, under general anesthesia\n* No allergy to one of the medications used in this study\n\nExclusion Criteria:\n\nContraindication to the use of the study drug (esmolol) is an exclusion criterion :\n\n* Hypotension\n* Sinus bradycardia\n* Sick sinus syndrome\n* Second and third degree A-V block\n* Pulmonary hypertension\n* Right ventricular failure secondary to pulmonary hypertension\n* Decompensated heart failure\n* Cardiogenic shock\n* Nontreated pheochromocytoma\n* Known hypersensitivity to esmolol or any of the inactive ingredients of the product\n* Allergy to esmolol or other beta blockers (cross-sensitivity is possible)\n* Renal dysfunction\n* Airway disease such as asthma or chronic obstructive pulmonary disease\n* Thyrotoxicosis\n* Myasthenia gravis\n* Raynaud's disease or peripheral circulatory disorder\n\nOther situations leading to exclusion :\n\n* Severe mental impairment\n* Chronic use of opioids, β-adrenergic receptors antagonists\n* High risk of conversion to laparotomy according to the surgical team (\\>25%)\n\nPatients will automatically be excluded after recruitment if they withdraw their consent, or if laparoscopy is converted to laparotomy.","65 Years",{"count":223,"type":21},64,[225],"PHASE4","This study aims to evaluate esmolol's perfusion impact during induction and maintenance of general anesthesia, using Nociception-Level-guided control of nociception, in adult patients undergoing laparoscopic and lower abdominal surgery, on intraoperative remifentanil consumption and postoperative pain in the Post-Anesthesia Care Unit.",[228,79,27],"Opioid Use, Unspecified",[230,231,232,233],"opioid sparing anesthesia","beta blockers","nociception monitoring","general anesthesia","2024-07-15",{"date":236,"type":33},"2024-07-16",{"date":238,"type":33},"2024-04-16",{"date":240,"type":21},"2025-03-04",{"name":242,"class":40},"Ciusss de L'Est de l'Île de Montréal",{"id":244,"slug":245,"hasResults":11,"nctId":246,"briefTitle":247,"officialTitle":248,"acronym":249,"eligibilityCriteria":250,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":251,"enrollmentInfo":252,"targetDuration":4,"studyType":106,"phases":254,"briefSummary":255,"conditions":256,"keywords":257,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":261,"lastUpdatePostDateStruct":262,"startDateStruct":264,"completionDateStruct":266,"leadSponsor":268,"locationsCount":41},"100544353","cervicalthoracic-neuromodulation-and-nociceptive-processing-100544353","NCT06367777","Cervical\u002FThoracic Neuromodulation and Nociceptive Processing","Investigating the Effects of the Neuromodulation of the Cervical and the Low-thoracic Spinal Cord on Nociceptive Processing in Healthy Volunteers - an Randomized, Sham-controlled, Double-blinded Study","MICROVOLT2","Inclusion Criteria:\n\nHealthy young adults\n\nExclusion Criteria:\n\n* Known medical conditions (e.g., diabetes, neuropathy, psychiatric disorders, seizure, migraine, pacemaker or other implanted medical devices...)\n* Use of any medication (except contraception)","40 Years",{"count":253,"type":21},24,[108],"Several studies have demonstrated that direct currents delivered through the skin at the level of the low-thoracic spinal cord can influence spinal cord function. In human volunteers, anodal low-thoracic transcutaneous spinal direct current stimulation (tsDCS) alters spinal processing of nociceptive inputs. Whether cervical tsDCS is able to do the same is less well known. In this double-blinded, sham-controlled and cross-over trial, the investigators will compare the effects on the nociceptive processing of healthy volunteers of cervical and low-thoracic tsDCS.",[27],[258,259,260],"tsDCS","non-invasive neuromodulation","healthy volunteers","2024-06-20",{"date":263,"type":33},"2024-06-21",{"date":265,"type":33},"2024-06-19",{"date":267,"type":21},"2024-10",{"name":269,"class":40},"Université Catholique de Louvain"]